Neurodegenerative Diseases: therapy development

2024 Activity indicators

10 competitive projects led: ISCIII, MICINN, UCM
3 private projects led
10 HR competitive contracts
10 publications
IF: 47.70
Q1 publications: 7 (70%)
D1 publications: 3 (30%)
1 thesis
8 awards to group members
Evaluators in national and European institutions: 4 PI
Members of editorial committees: 2 PI
1 patent GB201912244 with title: "Use of cannabinoids
in the treatment of dyskinesia associated with Parkinson's disease
" with PCT/GB2020/052039, extended in three territories
13 visitors received and 58 months stay:
- Universidad Complutense de Madrid
- Universidad Nacional del Litoral UNL. Santa Fé. Argentina
- Vrije Universiteit Brussel. Belgium
- Escuela Técnica de Enseñanzas Especializadas
4 months of stay in foreign centres:
- Department of Veterinary Medical Sciences (Anatomy Service), University of Bologna. Bolonia (Italy)
- University of Genoa Department of Pharmacy (DIFAR) Génova (Italy)

Milestones

Gonzalo C, Santos I, García L, Martín R, Rodríguez C, Wittwer MB, Dzygiel P, Grether U, de Lago E, Fernández J. Involvement of CB(1) and CB(2) receptors in neuroprotective eff ects of cannabinoids in experimental TDP-43 related frontotemporal dementia using male mice. Biomed Pharmacother. 2024;174: 116473 - 116473. DOI:10.1016/j.biopha.2024.116473. E8.
Burgaz S, Navarro E, Rodríguez S, Navarrete C, Garrido M, Lastres I, Chocarro J, Lanciego JL, Muñoz E, Fernández J. Investigation in the cannabigerol derivative VCE-003.2 as a disease-modifying agent in a mouse model of experimental synucleinopathy.
Silva I, Martín R, Berrojo A, Rodríguez C, Fernández J, De Lago E, Lastres I. Benefi cial Eff ect of Dimethyl Fumarate Drug Repositioning in a Mouse Model of TDP-43-Dependent Frontotemporal Dementia. Antioxidants (Basel). 2024;13(9): 1072. DOI:10.3390/ant.
Aebi J, Atz K, Ametamey SM, Benz J, Blaising J, Butini S, Campiani G, Carreira EM, Collin L, de Lago E, Gazzi T, Gertsch J, Gobbi L, Guba W, Fernández J, Fingerle J, Haider A, He Y, Heitman LH, Honer M, Hunziker D, Kuhn B, Maccarrone M, Märki HP, Martin RE, Mohr P, Mu L, Nazaré M, Nippa DF, Oddi S, O'Hara F, Pacher P, Romero J, Röver S, Rufer AC, Schibli R, Schneider G, Stepan AF, Sykes DA, Ullmer C, Van der Stelt M, Veprintsev DB, Wittwer MB, Grether U. Enhancing Drug Discovery and Development through the Integration of Medicinal Chemistry, Chemical Biology, and Academia-Industry Partnerships: Insights from Roche's Endocannabinoid System Projects. Chimia (Aarau). 2024;78(7-8): 499 - 512. DOI:10.2533/chimia.2024.499.
Choya C, Navarro E, Ríos CL, López MG, Egea J, Hernansanz P, Martínez A. The mitochondrial Na(+)/Ca(2+) exchanger NCLX is implied in the activation of hypoxia-inducible factors. Redox Biol. 2024;77: 103364 - 103364. DOI:10.1016/j.redox.2024.103364.

Bibliometrics

	Articles	ACCUM. FI	MEAN IF	ARTICLES Q1 OR Q2	% IN Q1 OR Q2	ARTICLES D1	% IN D1
2020	6	29.85	4,98	6	100	1	17
2021	12	74.50	6.21	12	100	3	25
2022	5	27.33	5.47	5	100	0	0
2023	5	23.51	5.88	3	60	1	20
2024	10	47.70	5.96	7	70	3	30
	38	202.89	5.70	33	87	8	21